Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Briumvi (ublituximab-xiiy) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Ublituximab was among the top three most effective monoclonal antibody therapies for reducing the annualized relapse rate (ARR), with a significant effect size favoring ublituximab (Cohen's d = -0.17, P = 0.006).
• Ublituximab demonstrated significant reductions in MRI outcomes at week 96, showing less disease activity in T1 lesions (Cohen's d = -0.43, P < 0.00001) and T2 lesions (Cohen's d = -0.55, P < 0.00001) compared to Teriflunomide.
• The likelihood of achieving no evidence of disease activity (NEDA) by two years post-initiation was significantly higher with ublituximab, with an odds ratio of 3.33 (P < 0.00001).
• There is no safety information available in the reviewed studies.
• There is no population types or subgroups information available in the reviewed studies.